Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Julie Fasone, a director of Eastman Chemical Company (EMN), purchased 1,453 shares of the company's common stock on 08/27/2025 at a reported price of $68.8 per share. After this purchase she beneficially owned 17,546 shares in a direct ownership capacity. The Form 4 was filed as a single reporting person filing and the form was signed on behalf of Ms. Fasone by Mark D. Austin by power of attorney on 08/28/2025. The report discloses no derivative transactions and provides no additional remarks.
Eric L. Butler, identified as a director of Eastman Chemical Co. (EMN), reported a purchase of 3,000 shares of Common Stock on 08/27/2025 at a price of $68.6525 per share. Following the transaction, the filing reports 9,330 shares beneficially owned, held directly. The Form 4 was signed by Power of Attorney Mark D. Austin on 08/28/2025.
Brett D. Begemann, a director of Eastman Chemical Company (EMN), reported a purchase of 1,500 shares of the issuer's common stock on 08/27/2025 at a reported price of $68.285 per share. After the transaction, Mr. Begemann beneficially owned 9,520 shares. The Form 4 was signed on behalf of Mr. Begemann by Mark D. Austin under power of attorney on 08/28/2025.
Damon J. Audia, a director of Eastman Chemical Company (EMN), purchased 1,465 shares of common stock on 08/27/2025 at a price of $68.585 per share. After the transaction he beneficially owned 1,597 shares. The Form 4 was signed under power of attorney by Mark D. Austin on 08/28/2025. The filing reports a direct acquisition by a director and does not disclose derivative transactions.
Julie A. McAlindon, SVP, Regions & Chief Supply Chain Officer and director of Eastman Chemical Co. (EMN), purchased 2,000 shares of the issuer's common stock on 08/27/2025 at a reported price of $68.4294 per share. After the transaction she beneficially owned 12,731 shares directly and had indirect ownership of 867 shares through an ESOP. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025.
Insider purchase reported: Eastman Chemical Co. (EMN) executive Brad A. Lich purchased 3,280 shares of Common Stock on 08/27/2025 at a reported price of $68.49 per share. After the transaction, Mr. Lich beneficially owned 83,487 shares directly, plus 2,540 shares held through a 401(k) plan and 1,223 shares held through an ESOP.
Form 4 summary: William T. McLain Jr., Executive Vice President and Chief Financial Officer of Eastman Chemical Company (EMN), reported the purchase of 3,670 shares of Eastman common stock on 08/27/2025 at an average weighted price of $68.73 per share. The filing states the shares were bought at prices ranging from $68.33 to $69.16. Following the transaction, Mr. McLain beneficially owns 53,524 shares. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025. The filing discloses no derivative transactions.
Mark J. Costa, CEO and Board Chair of Eastman Chemical Company (EMN), purchased 7,400 shares of the company's common stock on 08/27/2025 at a price of $67.89 per share. After the transaction, Mr. Costa beneficially owned 453,986 shares directly and an additional 3,153 shares indirectly through an ESOP. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025.
The filing records a routine insider purchase rather than a sale or derivative activity; no options, warrants, or other derivative transactions are reported. The disclosure shows the reporting person's roles as Director and CEO & Board Chair, confirming insider status and materiality for investor monitoring of executive transactions.
Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 4,246,293 shares of Eastman Chemical Company common stock, representing 3.7% of the 115,459,908 shares believed outstanding. The filing lists the holder as Capital Research Global Investors, a division of Capital Research and Management Company, and provides issuer and filer addresses.
The filing certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The document is signed by Jae Won Chung on behalf of Capital Research Global Investors with a signature date of 08/05/2025.